RxDoctor Payments Data

Hyesoon Choi

Psychiatric/Mental Health · Everett, WANPI 1851699573

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 396 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,997in general payments, 2019–2025

Across 396 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$771
  • Axsome Therapeutics, Inc.$753
  • Alkermes, Inc.$445
  • Corium, LLC$407
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$7,92399%
  • Education$741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,997 in reported general payments places this provider in the 95th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate13$24,631
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine29$2,551
Desvenlafaxine ErDesvenlafaxine12$1,751
Zolpidem Tartrate ErZolpidem Tartrate24$1,657
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine45$1,579
Alprazolam38$567
Methylphenidate Hcl23$511
Olanzapine12$497
Bupropion Hcl SrBupropion Hcl20$486
Guanfacine Hcl19$445
Quetiapine Fumarate34$407
Clonazepam45$317
Lamotrigine39$263
Divalproex Sodium12$201
Bupropion XlBupropion Hcl24$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,512$24,63113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Everett

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →